Clinicopathologic and Ancillary Testing of Primary Clear Cell Carcinoma of the Cervix
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Electronic Health Record Review, Laboratory Biomarker Analysis.
- Who it may be relevant to
- Registry conditions: Human Papillomavirus-Independent Cervical Adenocarcinoma, Clear Cell-Type. Basic parameters: No limits · Female.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- United States
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Clinicopathologic and Ancillary Testing of Primary Clear Cell Carcinoma of the Cervix - a Rare Tumor
Overview
This study aims to provide a comprehensive report on clinicopathologic features, immunohistochemical/biomarker testing and molecular profile of cervical clear cell carcinoma. This study may help researchers learn more about the molecular profile of cervical clear cell carcinoma.
Detailed description
PRIMARY OBJECTIVE:
I. To perform a retrospective clinicopathologic study on patients diagnosed and treated for clear cell carcinoma of the cervix at M D Anderson Cancer Center (MDACC) and to delineate the immunohistochemical and molecular profile of these cases.
OUTLINE:
Patients' medical records are reviewed retrospectively, and archival tumor tissue analyzed by immunohistochemistry and next generation sequencing.
Interventions
- Other Electronic Health Record Review
Medical records reviewed - Other Laboratory Biomarker Analysis
Correlative studies
Primary outcome measures
- Clinicopathologic study on patients diagnosed and treated for clear cell carcinoma of the cervix [Time frame: through study completion, an average of 1 year]
Eligibility criteria
Inclusion criteria
- Patients diagnosed with clear cell carcinoma of the cervix at MDACC
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Observational model
- Case-only
Study locations
United States · 1 center
- M D Anderson Cancer Center — Houston
Identifiers
NCT: NCT05046080 · 2020-0989 · NCI-2021-08814 · 2020-0989